Understanding the genetic factors in a rare type of kidney cancer
Resolving phenotypic overlap in renal carcinoma subtypes using multi-tiered network methods
This study is looking at a rare type of kidney cancer called Translocation Renal Cell Carcinoma (tRCC) to find out how certain genes affect its growth, which could help doctors make better diagnoses and create more effective treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11033442 on NIH RePORTER |
What this research studies
This research focuses on Translocation Renal Cell Carcinoma (tRCC), a rare and aggressive kidney cancer that is often misdiagnosed due to its overlapping characteristics with other cancer subtypes. The study aims to identify specific gene regulatory elements and transcription factors that contribute to the progression of tRCC. By developing a novel optimization method, researchers will analyze gene expression data to better understand the activity of these factors, even with small sample sizes. This approach could lead to more accurate diagnoses and targeted therapies for patients with tRCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Translocation Renal Cell Carcinoma or those exhibiting symptoms consistent with this rare cancer.
Not a fit: Patients with other types of kidney cancer that do not involve the specific genetic factors associated with tRCC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic accuracy and more effective treatment options for patients with Translocation Renal Cell Carcinoma.
How similar studies have performed: Previous research has shown promise in identifying genetic factors in other cancer types, suggesting that this approach could yield valuable insights for tRCC as well.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Ben Guebila, Marouen — Dana-Farber Cancer Inst
- Study coordinator: Ben Guebila, Marouen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.